A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

Study Summary

Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.

Conditions

Obesity Overweight Chronic Weight Management

Interventions / Drugs

aleniglipron or placebo aleniglipron or placebo aleniglipron or placebo aleniglipron or placebo

View on ClinicalTrials.gov ↗

Sponsor

GPCR

Structure Therapeutics

GPCR Therapeutics

C60/100

Study Details

Enrollment82 participants

Primary Completion—

Lead SponsorGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Data Retrieved2026-04-11 04:14:51.096552+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.